Zydus Cadila has received final USFDA approval to market fluconazole tablets used for the treatment of fungal infections in USA market. The company also received approval for Clobetasol Propionate spray used in the treatment of various skin disorders. The company will market to fluconazole tablets in strengths of 50 mg, 100 mg, 150 mg and 200 mg and Clobetasol Propionate spray, 0.05 per cent.
Company Profile : Cadila Healthcare Ltd
Leave a Reply